The episode explores how GLP-1 weight loss drugs like Ozempic and Wegovy, initially developed for diabetes, have evolved into a cultural and medical phenomenon, with expanding access due to competition, generics, and political intervention—though at great cost to Novo Nordisk, the pioneer
Sign up to read the full summary
Free AI-powered recaps of every episode, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.
Guest
Eshe Nelson
narrative on The Daily
Mentions
Books, people, and resources mentioned in this episode.
People
Companies
Products & Tools
Topics
Listen to This Episode
More from The Daily
Marriage and Sex in the Age of Ozempic: An Update
Congress Failed to Extend the Health Care Subsidies. Now What?
TrumpRx Opens for Business
Can We Reverse Aging?
The Millions of Poor Americans at the Mercy of the Shutdown
From Serial: 'The Preventionist'
Related episodes
From other shows on similar topics.
What we got wrong about GLP-1s
Search Engine
Novo Nordisk's CEO Has a Comeback Plan
The Journal.
664. Are Thousands of Medical Cures Hiding in Plain Sight?
Freakonomics Radio
Got Ozempic Breath? & Goblins Infiltrate ChatGPT
Morning Brew Daily
The Evidence on Ozempic to Treat Addiction
The New Yorker Radio Hour
#374 - "Doctors Are Legally BANNED From Telling You This" - Pharma Whistleblower | Brigham Buhler
Danny Jones Podcast
Get summaries like this every morning.
Free AI-powered recaps of The Daily and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.